Catalent, Inc. (CTLT)

108.11 -1.11 (-1.02%) As of 12:30PM EDT. Market open.

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 19,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John R. Chiminski	Exec. Chair of the Board	3.17M	22.37M	1964
Mr. Alessandro Maselli	CEO & Director	3.78M	N/A	1972
Mr. Thomas P. Castellano	Principal Accounting Officer, Sr. VP & CFO	731.92k	483.08k	1980
Mr. Steven L. Fasman Esq.	Exec. VP & Chief Admin. Officer	1.32M	2.43M	1963
Mr. Ricky Hopson	Pres & Division Head for Clinical Devel. and Supply	N/A	N/A	1976
Mr. Julien Meissonnier	VP & Chief Scientific Officer	N/A	N/A	N/A
Mr. Charles Lickfold	Sr. VP & Chief Information Officer	N/A	N/A	N/A
Mr. Paul Surdez	VP of Investor Relations	N/A	N/A	N/A
Mr. Michael J. Grippo	Sr. VP of Strategy & Corp. Devel.	N/A	N/A	1969
Mr. Ricardo Pravda	Sr. VP & Chief HR Officer	N/A	N/A	1972

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Corporate governance

Catalent, Inc.’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 4; Board: 10; Shareholder rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.